PBYI vs VRTX · P/E 4.3, rev $56.5M vs P/E 30, rev $3.33B
Puma Biotechnology Inc (PBYI) versus Vertex Pharmaceuticals Inc (VRTX) — a side-by-side from cached financials, not a winner call.
Puma Biotechnology Inc (PBYI) is a biotechnology company listed on US.
Vertex Pharmaceuticals Inc (VRTX) is a biotechnology company listed on US. It is led by Reshma Kewalramani FASN, M.D..
Latest reported PBYI revenue for 2026-06-30 was $56.5M. Net income was $8.2M. Revenue was up 26.1% from 2026-03-31 to 2026-06-30. PBYI currently screens at market cap $165.3M and trailing P/E 4.3.
Latest reported VRTX revenue for 2026-06-30 was $3.33B. Net income was $1.10B. Revenue was up 11.6% from 2026-03-31 to 2026-06-30. VRTX currently screens at market cap $106.87B and trailing P/E 29.7.
PBYI currently screens at market cap $165.3M and trailing P/E 4.3. VRTX currently screens at market cap $106.87B and trailing P/E 29.7.
Not investment advice. Open the PBYI and VRTX stock pages for the full models.
Not investment advice.